新型结合剂优化心力衰竭RAASi治疗:系统性审查和元分析
Stefania Paolillo1, Christian Basile1, Simona Dell'Aversana1
1Department of Advanced Biomedical Sciences, Federico II University of Naples, Naples, Italy.
European journal of internal medicine
|August 30, 2023
概括
新型结合剂在心力衰竭 (HF) 患者中有效优化了氨酸- ангиотензин- 阿尔多素系统抑制剂 (RAASi) 治疗. 这些结合剂减少了高血症事件和较低的水平,改善了治疗的坚持和结果.
科学领域:
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 药理学 药理学是指药理学的学科.
背景情况:
- 超血是心力衰竭 (HF) 患者的常见并发症,通常由氨酸-血管酶-阿尔多斯特系统抑制剂 (RAASi) 加剧.
- 水平升高会增加死亡风险,并可能导致停止必要的RAASi治疗.
- 新型结合剂 (NPB) 已被批准用于高血治疗,但它们对RAASi治疗优化的影响需要进一步评估.
结论:
- 在优化HF患者RAASi治疗方面,NPB是有效的.
- NPB显著降低高血症事件和较低的血清水平.
- 使用NPB支持持续的RAASi治疗,这对于HF管理至关重要.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
463
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
463
Heart Failure Drugs: Diuretics
420
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
420
Antihypertensive Drugs: Potassium-Sparing Diuretics
628
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
628
Heart Failure V: Medical Management
13
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
13
Antihypertensive Drugs: Direct Renin Inhibitors
679
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
679
Heart Failure Drugs: Inotropic Agents
618
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
618


